Double blind, placebo controlled trial of metronidazole in Crohn's disease.
about
Use of antibiotics in the treatment of Crohn's diseaseEpidemiology and clinical course of Crohn's disease: results from observational studiesPrimary treatment of Crohn’s disease: combined antibiotics taking center stageReplication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to AntibioticsProbiotics for the maintenance of remission in Crohn's diseaseThe intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directionsModulating Composition and Metabolic Activity of the Gut Microbiota in IBD PatientsRole of antibiotics for treatment of inflammatory bowel diseaseClassical and recent advances in the treatment of inflammatory bowel diseasesModulation of microbiota as treatment for intestinal inflammatory disorders: An uptodateMatrix metalloproteinases in inflammatory bowel disease: an updateMonocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn's diseaseComparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel diseaseRecent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?Medical management of Crohn's disease: current therapy and recent advances.A meta-analysis of randomized controlled trials comparing antibacterial therapy with placebo in Crohn's disease.How to do without steroids in inflammatory bowel disease.Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics.Conventional therapy for Crohn's diseaseAntibiotics and probiotics in treatment of inflammatory bowel disease.The intestinal microbiota plays a role in Salmonella-induced colitis independent of pathogen colonizationCrohn's disease-associated Escherichia coli survive in macrophages by suppressing NFκB signaling.Promotion of a favorable gut flora in inflammatory bowel disease.Bacteroides ovatus as the predominant commensal intestinal microbe causing a systemic antibody response in inflammatory bowel disease.Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli.Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice.Clinical evaluation and management of acute severe colitis.Alterations in the gut microbiome of children with severe ulcerative colitisThe role of bacteria and pattern-recognition receptors in Crohn's disease.Infectious etiopathogenesis of Crohn's diseaseRecent advances in inflammatory bowel disease.Review article: the management of severe Crohn's disease.What options do we have for induction therapy for Crohn's disease?The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis.Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis.European evidence based consensus on the diagnosis and management of Crohn's disease: current management.Perturbation of the human microbiome as a contributor to inflammatory bowel diseaseEvidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.Review article: medical treatment of active Crohn's disease.Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis.
P2860
Q22241216-4931EF26-66E3-42F5-8CB1-8F2EA19F91A0Q22241217-B60C57F5-763D-4F85-A497-925A7C9757F2Q22241483-ED47B32A-66AD-41AE-89E2-E5D5ECD1A35DQ22242242-0FFA5AAF-AEE8-4406-AE31-B214DAA35D3DQ24246901-39C6A56E-2F6E-417E-9E01-94270DCDC628Q26745700-2C5E28C3-C7BE-47AC-A6EA-01E0B3852E48Q26750985-D240CA5B-99BD-4C86-B018-95568F943BA0Q26774552-D10A78EF-0945-4A01-B1B5-670228E5B285Q26861725-5683D154-BE1A-4939-9280-77ACC1405D76Q28072437-6F615735-2F0B-4F52-A877-50560D3F474CQ28080664-67706859-CDCD-4D16-A1DE-BBFB5BCFAEF1Q28359753-C6CDF397-9AF9-488A-945C-3ECD1A98E9D9Q28537737-281202E7-6EF8-4CAC-B646-D67417E0032DQ30242073-F77D4CD7-989F-458F-A3F9-788EFC5047CAQ30450875-597E8CDF-2FD1-410D-B129-AF1143E33189Q33521352-5E906A2A-A97B-42EC-B956-F7838CB82860Q33853564-35D5652A-C986-4D7A-8A6F-7656A64C2C70Q33855714-850F4C70-2585-4772-A496-7E2A5875530AQ33866982-977035A2-7B65-4C7F-8058-311ECA13E8BDQ33867934-3AC7947B-0324-4FD6-85D8-29213AE32305Q33919752-CB4CCA02-3B6C-4C6B-AEED-25F01EBB4597Q33922663-7E182722-BD28-41E5-AE53-255C4D357F87Q33941313-7A4BC086-85AB-4C83-9E8E-2DEA88306A3BQ33941528-BF609407-3810-4686-A92F-8139D9B817A5Q34001149-547BEBC4-D36C-4D22-981F-03492D635410Q34006798-49AE067D-6FF9-42D2-A74C-593278BA3466Q34015905-3AF99560-E665-4824-9BF5-22FC7638935FQ34101549-CD66A846-0D42-4105-B5D5-AED77AC44811Q34163374-522601D5-0A62-4C41-A14E-FAD3739D9467Q34168490-7569C856-A57A-4C69-B140-202189F7D8DFQ34188405-B0C19284-EBD7-4B00-BB5D-59AFFDED46F5Q34235823-3EE3B0E2-0E30-45E4-BC07-8EE2A071717EQ34307369-4F491199-8F89-4659-9C38-803FE88822C2Q34313840-BB3F993C-AD60-445E-921B-99658B6209C2Q34415570-B5B50B88-7733-428D-A424-E35E311F20FDQ34564902-F747D6A3-7BA8-41F4-BB8A-6002F1D82CAFQ34569117-26CFBD4D-D916-4201-AF3D-D76B8EA53923Q34652744-ABA078B7-D937-48D3-9043-70C5B4E6D9F2Q34669225-AF42D070-8AFD-490E-B497-5DC2540C723BQ34740052-172B3FB9-38B5-4470-9DD4-60948CFA7215
P2860
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
description
1991 nî lūn-bûn
@nan
1991 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
@ast
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
@en
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
@nl
type
label
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
@ast
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
@en
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
@nl
prefLabel
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
@ast
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
@en
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
@nl
P2093
P2860
P356
P1433
P1476
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
@en
P2093
Greenberger N
Mekhjian H
Sessions J
Singleton J
Sutherland L
P2860
P304
P356
10.1136/GUT.32.9.1071
P407
P577
1991-09-01T00:00:00Z